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Abstract
Background Early detection of acute myocardial infarc-
tion (AMI) using cardiac biomarkers of myocardial
necrosis remains limited since these biomarkers do not rise
within the first hours from onset of AMI. We aimed to
compare the temporal release pattern of the C-terminal
portion of provasopressin (copeptin) with conventional
cardiac biomarkers, including creatine kinase isoenzyme
(CK-MB), cardiac troponin T (cTnT), and high-sensitivity
cTnT (hs-cTnT), in patients with ST-elevation AMI.
Methods We included 145 patients undergoing successful
primary percutaneous coronary intervention (PCI) for a
first ST-elevation AMI presenting within 12 h of symptom
onset. Blood samples were taken on admission and at four
time points within the first 24 h after PCI.
Results In contrast to all other markers, copeptin levels
were already elevated on admission and were higher with a
shorter time from symptom onset to reperfusion and lower
systolic blood pressure. Copeptin levels peaked immedi-
ately after symptom onset at a maximum of 249 pmol/L
and normalized within 10 h. In contrast, CK-MB, cTnT,
and hs-cTnT peaked after 14 h from symptom onset at a
maximum of 275 U/L, 5.75 lg/L, and 4.16 lg/L, respec-
tively, and decreased more gradually.
Conclusions Copeptin has a distinct release pattern in
patients with ST-elevation AMI, peaking within the first
hour after symptom onset before conventional cardiac
biomarkers and falling to normal ranges within the first
day. Further studies are required to determine the exact role
of copeptin in AMI suspects presenting within the first
hours after symptom onset.
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Introduction
Acute myocardial infarction (AMI) is defined as a clinical
cardiac event that is the consequence of myocardial
necrosis caused by ischemia [1]. Its diagnosis is often
based on symptoms, signs, and findings on the electro-
cardiogram (ECG), but in some patients these findings are
non-diagnostic. In these patients, biochemical markers of
myocardial necrosis, of which cardiac troponin and
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creatine kinase isoenzyme (CK-MB) are the preferred
biomarkers, play a pivotal role [2, 3]. A major drawback
of these markers is their inability to detect myocardial
necrosis in the first hours after symptom onset, since these
cardiac biomarkers rise after hours from the onset of
myocardial injury. While the outcome of AMI patients has
improved considerably [4, 5], establishing a timely and
correct diagnosis remains a challenge in patients present-
ing early after symptom onset without typical ECG
findings.
Recently, the C-terminal portion of provasopressin
(copeptin), a marker of acute endogenous stress and car-
diovascular hemostasis [6], has emerged as a promising
diagnostic marker for the detection of AMI in addition to
conventional cardiac biomarkers of myocardial necrosis in
patients presenting early after symptom onset [7, 8]. In
these studies, addition of copeptin to cardiac troponin T
(cTnT) improved the diagnostic accuracy of a measure-
ment on admission in patients presenting with chest pain to
an emergency department, especially in patients presenting
within 3 h after symptom onset. However, although these
studies have suggested that copeptin levels are elevated
much earlier than CK-MB or cTnT and drop in the 6 h
thereafter in patients with AMI, a comparison of temporal
release patterns after the onset of AMI between copeptin
and conventional cardiac biomarkers has not been made for
more than 6 h, when levels were still elevated. We there-
fore studied the temporal release pattern of copeptin and
also studied its relationship with conventional cardiac
biomarkers including the newly available high-sensitivity
cTnT (hs-cTnT) by frequently sampling patients with ST-
elevation AMI within the first 24 h.
Methods
Patients and design
The HEBE III trial was a randomized clinical trial evalu-
ating the effect of a single bolus of erythropoietin after
successful percutaneous coronary intervention (PCI) for a
first AMI on left ventricular ejection fraction. The study
design and results of the main study have been previously
described [9]. In brief, patients were eligible for the par-
ticipation if undergoing successful primary PCI (defined as
post-procedural thrombolysis in myocardial infarction
(TIMI) flow 2/3 through the culprit coronary artery) for a
first AMI. AMI was defined as chest pain suggestive for an
AMI, symptom onset \12 h before hospital admission or
\24 h in case of ongoing ischemia, an ECG with ST-seg-
ment elevation [1 mV in 2 or more leads or a new left
bundle branch block, and TIMI flow grade 0 or 1 on diag-
nostic coronary angiography. Exclusion criteria included:
hemoglobin levels[17.1 g/dL ([10.6 mmol/L) before PCI,
anticipated additional revascularization within 6 weeks,
atrial fibrillation, cardiogenic shock, end stage renal failure
(creatinine [220 lmol/L), malignant hypertension, previ-
ous treatment with RhEPO, blood transfusion \12 weeks
before randomization, polycythemia vera, pregnancy or
breast-feeding, concomitant inflammatory or malignant
disease, the presence of other serious medical conditions,
and recent trauma or major surgery. Primary endpoint was
ventricular ejection fraction as assessed by planar radio-
nuclide ventriculography at 6 weeks after PCI. The trial
protocol was approved by the Medical Ethics Committee of
our institution and is in accordance with the Declaration of
Helsinki. In total, 529 patients were included in HEBE III.
The current study was performed on all patients enrolled in
the pre-specified neurohormonal substudy, with a total of
145 patients recruited at the University Medical Center
Groningen, the Netherlands. Informed consent was obtained
in all patients. There were no significant differences in
baseline characteristics between the main trial and the
current substudy.
Blood sampling and assays
Blood samples were taken immediately on admission and
at 3, 6, and 24 h after PCI. Routine laboratory parameters
including CK, CK-MB, and cTnT were determined with
automated clinical chemistry methods immediately after
withdrawal. Additional blood samples were collected using
pyrogen-free tubes containing ethylenediaminetetraacetic
acid plasma, and centrifuged and stored at -80C within
1 h of withdrawal until analysis was performed. Copeptin
was detected in EDTA plasma with a commercially
available sandwich immunoluminometric assay (CT-pro-
AVP, B.R.A.H.M.S GmbH, Hennigsdorf, Germany) as
described in detail previously [8, 10]. The analytical
detection limit of the assay was 0.4 pmol/L, and the
functional assay sensitivity (value with an interassay
coefficient of variation (CV) \20%) \1 pmol/L. In a ref-
erence population of 5,000 participants of the Gutenberg
Heart Study, the 95, 97.5, and 99th percentile were 9.8, 13,
and 18.9 pmol/L, respectively [7]. cTnT was measured
with an electrochemiluminescence immunoassay (Roche
Diagnostics, Mannheim, Germany). The analytical detec-
tion limit was 0.01 lg/L, the CV was 10% at 0.03 lg/L,
and the 99th percentile in a healthy reference population
was 0.01 lg/L. In addition, hs-cTnT was determined
(Roche Diagnostics). Hs-cTnT had a limit of detection of
0.003 lg/L, the 10% CV at 0.013 lg/L, and a 99th per-
centile cutoff point of 0.014 lg/L. For the current study,
hs-cTnT had an interassay CV of 7.8, 4.6, and 4.3%, at
concentrations of 0.0233, 1.869, and 0.1176 lg/L, respec-
tively. CK was measured by photometry and CK-MB by
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immunoinhibition (both Roche Modular P, Roche Diag-
nostics GmbH, Mannheim, Germany). The estimated glo-
merular filtration rate (eGFR) was calculated using the
simplified Modification of Diet in Renal Disease equation
[11].
Statistical analysis
Data are expressed as mean ± standard deviation or
median (interquartile range) for continuous data and as
number (percentage) for categorical variables. Copeptin
values on admission were divided into quartiles to assess
relationships with baseline characteristics. Continuous
variables were compared using the two-sided student t test
or Mann–Whitney U test if samples were not normally
distributed. Categorical variables were analyzed with the
Pearson v2 test. Correlation between continuous variables
was assessed with the Spearman’s rank correlation coef-
ficient. To analyze correlates of the copeptin level on
admission, the STATA validation bootstrapping program,
SWBOOT, was used to perform 100 bootstrapped repeats
of multi-variable stepwise linear regression on candidate
correlates of copeptin levels. After the SWBOOT run, the
resulting validated candidate independent variables that
were selected at least 50 times out of the 100 separate
models were included in the final model and again
entered into a stepwise linear regression model. In this
validation run, the same regression procedure was used
except that the alpha tail probability for an independent
variable to enter the model was set at the conventional
screening level of 0.05 and to remove of 0.1. STATA
bootstrap estimation was used to estimate 95% confidence
intervals. Continuous variables were introduced centered
in the regression model. Copeptin was log transformed
and centered. Time from symptom onset to blood sam-
pling was calculated for all individual patients according
to the actual sampling moment. A fractional polynomial
parameterization of exposure was applied to investigate
the relation between marker levels and the time from
symptom onset to sampling moment. Fractional polyno-
mials are a method of analyzing relationships that make
no a priori hypothesis about their shape [12]. With this
analysis, each exposure variable (copeptin, CK-MB,
cTnT, and hs-cTnT) is expressed a polynomial of degree
[1 to allow modeling of its non-linear relation. Because
data could be assumed to be clustered (i.e., within
patients), possible cluster effects were adjusted for by
applying robust standard errors (i.e., option ‘cluster’ in
the specific STATA regression commands). Statistical
significance was considered as a two-tailed p value \0.05.
Statistical analyses were performed with SPSS version
16.0.2 (Chicago, IL, USA) and STATA version 11.0
(College Station, Texas, USA).
Results
Baseline characteristics
From the 145 patients included in this study, a baseline
copeptin level was available in 130 patients. Baseline
characteristics of these patients, according to quartiles
of copeptin at hospital admission, are summarized
in Table 1. Mean age of the total population was
61 ± 12 years and 76% was male. Copeptin levels were
higher in patients with lower body mass index (BMI) and
lower blood pressure on the admission. Higher levels
of copeptin were particularly found in patients who pre-
sented early after onset of symptoms (Table 1). A shorter
symptom onset to reperfusion time was correlated with a
higher admission copeptin level (r = -0.431, p \ 0.001).
Copeptin levels on admission were not related to enzy-
matic infarct size as reflected in the peak of CK, CK-MB,
or cTnT (Table 2).
Correlates of admission copeptin level
Univariable correlates of copeptin levels on admission
included BMI, systolic and diastolic blood pressure, ante-
rior MI, and time from symptom onset to reperfusion
(Table 3). After multivariable adjustment, a higher co-
peptin level on admission was independently associated
with a lower BMI, lower systolic blood pressure, and a
shorter time from symptom onset to reperfusion.
Copeptin levels on admission compared to conventional
cardiac biomarkers
Copeptin levels on admission exceeded the 99th percentile
in 84.8% of patients reperfused within 3 h of symptom
onset and in 100% of patients with symptom onset of less
than 1 h (Table 4). In contrast, sensitivity was lower on
admission for cTnT (39.4%) and hs-cTnT (80.3%). Ele-
vation of copeptin and/or (hs-)cTnT beyond the 99th per-
centile reached the highest sensitivities at 90.9% for cTnT
and 98.5% for hs-cTnT.
Temporal release pattern of copeptin compared
to conventional cardiac biomarkers
Figure 1 shows the distinctively different temporal release
pattern of copeptin in comparison to CK-MB, cTnT, and
hs-cTnT. As illustrated, copeptin levels were at a maxi-
mum of 249 pmol/L immediately after symptom onset and
normalized to below the upper reference limit (99th per-
centile) within 10 h. In contrast, conventional cardiac
biomarkers increased to their maximal levels at 14–16 h of
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symptom onset at a maximum of 275 U/L, 5.75 lg/L, and
4.16 lg/L for CK-MB, cTnT, and hs-cTnT, respectively.
The temporal release patterns of cTnT and hs-cTnT
showed a similar curve. After 16 h, cardiac biomarker
levels decreased more gradually than copeptin, with CK-
MB falling slightly steeper than cTnT and hs-cTnT.
Discussion
Although copeptin has been recently described as a
potential biomarker for the early detection of AMI, there is
little detailed information about its release pattern during
the early hours after the onset of AMI. In this study, we
Table 1 Baseline patient characteristics according to quartiles of copeptin on admission
Copeptin
All (n = 130) B15.50 15.51–79.05 79.06–179.00 [179.00 p
Clinical
Age (years) 61 ± 12 61 ± 12 60 ± 9 63 ± 13 62 ± 12 0.799
Male sex [n (%)] 99 (76) 27 (82) 25 (78) 26 (79) 21 (66) 0.156
BMI (kg/m2) 27 (24–30) 29 (26–31) 28 (25–30) 28 (24–30) 25 (23–28) 0.001
Systolic blood pressure (mmHg) 122 ± 23 133 ± 23 125 ± 22 114 ± 17 116 ± 23 0.001
Diastolic blood pressure (mmHg) 72 ± 13 77 ± 12 73 ± 13 69 ± 11 68 ± 15 0.016
Heart rate (bpm) 78 ± 14 82 ± 14 78 ± 15 76 ± 12 75 ± 15 0.179
Previous revascularization [n (%)] 1 (1) 1 (3) 0 (0) 0 (0) 0 (0) 0.185
Hypertension [n (%)] 50 (39) 12 (36) 11 (37) 14 (44) 13 (41) 0.608
Diabetes [n (%)] 12 (9) 6 (18) 3 (10) 0 (0) 3 (9) 0.111
Current smoking [n (%)] 32 (25) 10 (30) 8 (27) 8 (25) 6 (19) 0.289
Family history [n (%)] 47 (37) 12 (36) 13 (43) 10 (31) 12 (38) 0.831
Hypercholesterolemia [n (%)] 22 (17) 7 (21) 6 (20) 7 (22) 2 (6) 0.153
Symptom onset to reperfusion (min) 180 (135–270) 265 (177–427) 205 (157–272) 150 (104–202) 155 (120–210) \0.001
Angiographic
No. of diseased vessels [n (%)] 0.911
1 86 (68) 22 (67) 23 (72) 20 (61) 21 (66)
2 33 (25) 8 (24) 6 (19) 10 (30) 9 (28)
3 11 (9) 3 (9) 3 (9) 3 (9) 2 (6)
Anterior AMI [n (%)] 61 (47) 12 (36) 12 (38) 18 (55) 19 (59) 0.029
Biochemical
eGFR (mL/min/1.73 m2) 95 ± 23 99 ± 24 95 ± 24 95 ± 25 88 ± 17 0.298
Sodium (mmol/L) 139 ± 2 138 ± 2 139 ± 2 140 ± 2 140 ± 2 0.005
NT-proBNP (ng/L) 98 (57–324) 178 (68–402) 79 (49–146) 93 (43–421) 92 (40–215) 0.140
Data are expressed as mean ± SD, median (interquartile range), or number (percentage)
AMI acute myocardial infarction, BMI body mass index, eGFR estimated glomerular filtration rate, NT-proBNP N-terminal pro-B-type natriuretic
peptide, PCI percutaneous coronary intervention
Table 2 Relationship between admission copeptin level and enzymatic infarct size
Copeptin
All (n = 130) B15.50 15.51–79.05 79.06–179.00 [179.00 p
Max CK (U/L) 1,526 (872–2,935) 1,522 (903–3,094) 1,423 (868–2,738) 1,686 (786–2,753) 1,472 (733–3,206) 0.731
Max CK-MB (U/L) 206 (112–323) 219 (132–329) 210 (109–299) 178 (102–329) 209 (89–344) 0.581
Max troponin T (lg/L) 4.9 (2.0–7.9) 4.9 (2.5–8.3) 4.4 (2.3–8.1) 5.3 (2.0–7.0) 3.9 (1.6–9.1) 0.537
Data are expressed as median (interquartile range)
CK creatine kinase, CK-MB creatine kinase isoenzyme
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demonstrate that in patients with successfully reperfused
ST-elevation AMI within 12 h of symptom onset, the
release pattern of copeptin is distinctively different from
currently available cardiac biomarkers. Copeptin levels
peaked within the first hour after symptom onset and fell to
normal ranges after 10 h. In contrast, levels of CK-MB,
cTnT, and hs-cTnT peaked after more than 14 h and
decreased more gradually. Furthermore, a higher copeptin
level on admission is related to a shorter time from
symptom onset to reperfusion and a lower systolic blood
pressure.
Copeptin is derived from the C-terminal portion of the
precursor of vasopressin, one of the most important hor-
mones in regulating osmotic and cardiovascular homeo-
stasis and also released in response to acute endogenous
stress [6, 13]. Synthesized in the hypothalamus from the
precursor peptide pre-provasopressin, both peptides are
released by the neurohypophysis into the circulation. While
its exact function is largely unknown, copeptin acts as a
stable surrogate marker for vasopressin [10]. Furthermore,
copeptin has been reported as a biomarker in a variety of
clinical conditions including sepsis, lower respiratory tract
infections, and acute exacerbations of chronic obstructive
pulmonary disease [14–19]. The exact trigger for copeptin
release in AMI is unknown. Generally considered a marker
of acute endogenous stress, copeptin may be released in
response to stress occurring with the onset of AMI [8, 13].
However, copeptin also responds rapidly to changes in
fluid status and plasma osmolality [20, 21]. Our findings,
indicating that higher copeptin levels are independently
related to a lower systolic blood pressure, are consistent
with these reports. Therefore, the quick elevation of co-
peptin levels in AMI may also be triggered by hemody-
namic changes occurring after a drop in blood pressure, or
even earlier with elevation of left ventricular end-diastolic
pressure after coronary occlusion [22].
This study confirms and extends the findings of recent
previous studies, which reported that copeptin levels in
AMI patients were maximal on admission in contrast to
cTnT [7, 8] and dropped to a plateau level after the first day
[23]. The current study, however, is the first to describe the
temporal release pattern of copeptin in detail over the first
Table 3 Univariable and multivariable correlates of copeptin (log transformed)
Univariable Multivariable Number of
times selected
Coefficient 95% CI p Coefficient 95% CI p
BMI (kg/m2) -0.135 -0.193 to -0.0773 \0.001 -0.124 -0.172 to -0.077 \0.001 94
Systolic blood
pressure (mmHg)
-0.024 -0.034 to -0.013 \0.001 -0.021 -0.030 to -0.012 \0.001 82
Diastolic blood
pressure (mmHg)
-0.031 -0.050 to -0.012 0.002
Heart rate (bpm) -0.024 -0.042 to -0.006 0.008
Anterior AMI 0.556 0.056 to 1.056 0.030
Time from symptom
onset to reperfusion (h)
-0.192 -0.283 to -0.101 \0.001 -0.162 -0.247 to -0.076 \0.001 86
Admission sodium (mmol/L) 0.173 0.070 to 0.275 0.001
AMI acute myocardial infarction, BMI body mass index, CI confidence interval
Table 4 Sensitivities of
biomarkers on admission in the
early hours after symptom onset
Data are expressed as number/
total number (percentage)
cTnT cardiac troponin T,
hs-cTnT high-sensitivity
cardiac troponin T
Copeptin levels exceeding the
a 99th (18.9 pmol/L), b 97.5th
(13 pmol/L), and c 95th
(9.8 pmol/L) percentile
\1 h \2 h \3 h
Copeptina 10/10 (100) 34/37 (91.9) 56/66 (84.8)
Copeptinb 10/10 (100) 34/37 (91.9) 59/66 (89.4)
Copeptinc 10/10 (100) 36/37 (97.3) 61/66 (92.4)
cTnT 3/10 (30) 10/37 (27.0) 26/66 (39.4)
hs-cTnT 7/10 (70) 29/37 (78.4) 53/66 (80.3)
Copeptina or cTnT 10/10 (100) 34/37 (91.9) 60/66 (90.9)
Copeptinb or cTnT 10/10 (100) 34/37 (91.9) 62/66 (93.9)
Copeptinc or cTnT 10/10 (100) 36/37 (97.3) 64/66 (97.0)
Copeptina or hs-cTnT 10/10 (100) 37/37 (100) 65/66 (98.5)
Copeptinb or hs-cTnT 10/10 (100) 37/37 (100) 65/66 (98.5)
Copeptinc or hs-cTnT 10/10 (100) 37/37 (100) 65/66 (98.5)
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24 h after symptom onset in AMI and in comparison to the
release patterns of CK-MB, cTnT, and hs-cTnT. Copeptin
levels in the current study were approximately fourfold
higher than in these previous studies, most likely because
our population consisted of patients with ST-elevation AMI
only instead of a mixed population of AMI with and
without ST-elevation. It has been reported that copeptin
levels are higher for ST-elevation AMI than for non-ST-
elevation AMI [8].
To date, conventional cardiac biomarkers have limited
ability in immediately ruling out AMI in patients present-
ing early with symptoms that are suggestive for an AMI but
with non-diagnostic findings on ECG. The current findings
together with the previous studies suggest that copeptin
may be a potentially valuable marker on top of cTnT for
the detection of AMI. Copeptin levels are not elevated in
patients with exercise-induced ischemia [20] but are sig-
nificantly higher in patients with a suspected acute coro-
nary syndrome (ACS) presenting to an emergency
department in those with a final diagnosis of AMI than in
those with a different final diagnosis, including unstable
angina and other cardiac and non-cardiac causes of chest
pain [7, 8]. In these patients, adding a copeptin to a cTnT
measurement on admission improved the discriminative
value compared to a cTnT measurement alone and was of
superior value in ruling out AMI. With the combination of
copeptin and cTnT, the negative predictive value of a
single measurement on admission increased from 88.5 to
95.8% for all AMI suspects and from 82.4 to 92.4% for
suspects presenting within 3 h after symptom onset [8].
The current study illustrates and substantiates these find-
ings, since we confirm that, in patients with an AMI, co-
peptin is already strongly elevated in the very early phase,
while cTnT levels are still low. Because troponin assays
lack sensitivity in the early hours after onset of AMI,
adding a marker that is sensitive in these early hours and
acts independently from cardiomyocyte injury to this
conventional biomarker of myocardial necrosis may com-
plement and improve the diagnostic accuracy of a mea-
surement on admission.
Consistent with the other studies [3, 24], this study
indicates that CK-MB and cTnT begin to rise within sev-
eral hours after the onset of myocardial injury and reach
their peak value in the first 24 h. Concordantly, hs-cTnT
follows a similar release pattern as cTnT, despite a higher
sensitivity and improved precision at the lower limit of
detection [25–27]. The only conventional cardiac bio-
marker that could approach the early presence of marker
levels above normal ranges is myoglobin, whose levels
begin to rise 1 h after myocardial injury [3]. Despite its
quick release into the circulation, however, myoglobin is
not of additional value in a diagnostic strategy including
cardiac troponin and is not recommended as a diagnostic
biomarker in the routine clinical practice [28]. Whether
copeptin in conjunction with a high-sensitivity troponin
assay improves the diagnosis of ACS as suggested [7, 29]
deserves further investigation.
Limitations
Several limitations should be acknowledged as a result of
the inclusion and exclusion criteria of the present main
study. First, specificity could not be calculated for copeptin
and cardiac biomarkers in this study as all patients had a
final diagnosis of ST-elevation AMI. Previous studies have
indicated that copeptin has a low specificity and is more
appropriate as a biomarker to rule out AMI. Second,
assessment of copeptin has no value in the clinical practice
when ST-elevations are present on the ECG, but it is of
potential interest when patients present early and other
electrocardiographic and laboratory parameters are yet at
normal levels. The temporal release pattern described here
is only investigated for ST-elevation AMI and not for non-
ST-elevation AMI. In addition, the infarct-related artery
was (nearly) completely occluded at presentation in all
patients. In a more unselected AMI population with ST-
elevation, where a significant proportion of patients present
with an open infarct-related artery, it can be speculated that
baseline copeptin levels are lower, similar to the lower
copeptin levels found in non-ST-elevation AMI [8], in
which the infarct-related artery is usually open. Further
studies in AMI patients with and without ST-elevation
could clarify whether the lower copeptin levels in non-ST-
elevation AMI is the result of patency of the infarct-related
artery or of a longer time from symptom onset to admis-
sion. Third, primary PCI successfully achieved reperfusion
through the infarct-related artery in all patients. Whether
Fig. 1 Temporal release pattern of copeptin versus CK-MB, cTnT,
and hs-cTnT. The dashed horizontal line represents the upper
reference limit (99th percentile) for copeptin. CK-MB, creatine
kinase isoenzyme; cTnT, cardiac troponin T; hs-cTnT, high-sensitiv-
ity cardiac troponin T
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the quick normalization of copeptin levels is the mere
result of increasing time after onset of AMI or is a specific
response to successful primary PCI or other forms of
reperfusion requires further investigation. Fourth, the lim-
ited number of clinical events in this patient group did not
allow us to assess relationships between copeptin levels
and the clinical outcome. Copeptin levels on admission
have already been reported to be a strong prognostic
marker of mortality in cardiovascular patients (with and
without heart failure) surviving an AMI [23, 30, 31]. Fifth,
we are unable to explain why BMI is a strong determinant
of copeptin levels on admission. While the same is
observed for BMI and N-terminal pro-B-type natriuretic
peptide [32], the inverse relation between BMI and bio-
markers is poorly understood. Finally, we did not analyze
the temporal release pattern of myoglobin as this was not a
routine measurement in our center and there was insuffi-
cient frozen material stored to allow this additional
analysis.
In conclusion, copeptin is elevated in the early hours
after the onset of an ST-elevation AMI when other con-
ventional cardiac biomarkers, including CK-MB and cTnT,
are still low.
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